FDA Approves Novavax COVID Vaccine for High-Risk Groups

  • On 19th May 2025, the FDA granted full approval to Novavax's Nuvaxovid for use in older adults and high-risk individuals, marking a major milestone for the protein-based COVID-19 vaccine.
  • The U.S. Food and Drug Administration approved the Biologics License Application (BLA) for Nuvaxovid, Novavax’s COVID-19 vaccine, for adults aged 65 and older and for individuals aged 12 to 64 with at least one high-risk condition.
  • Eligible high-risk conditions include asthma, cancer, diabetes, obesity, and smoking history, which increase the risk of severe COVID-19 outcomes.
  • This approval triggered a $175 million milestone payment from Sanofi to Novavax, as part of their collaboration and license ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content

Already a Member? Login here

Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Be an Annual Subscriber

Science & Technology